Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease

Seong Hun Chang, In Soo Jung, Gi Yeon Han, Nam Hee Kim, Hyun Jung Kim, Chan Wha Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Alzheimer's disease (AD) involves regionalized neuronal death, synaptic loss, and an accumulation of intracellular neurofibrillary tangles and extracellular senile plaques. Although there have been numerous studies on tau proteins and AD in various stages of neurodegenerative disease pathology, the relationship between tau and AD is not yet fully understood. A transgenic mouse model expressing neuron-specific enolase (NSE)-controlled human wild-type tau (NSE-htau23), which displays some of the typical Alzheimer-associated pathological features, was used to analyze the brain proteome associated with tau tangle deposition. Two-dimensional electrophoresis was performed to compare the cortex proteins of transgenic mice (6- and 12-month-old) with those of control mice. Differentially expressed spots in different stages of AD were identified with ESI-Q-TOF (electrospray ionization quadruple time-of-flight) mass spectrometry and liquid chromatography/tandem mass spectrometry. Among the identified proteins, glutathione S-transferase P 1 (GSTP1) and carbonic anhydrase II (CAII) were down-regulated with the progression of AD, and secerin-1 (SCRN1) and V-type proton ATPase subunit E 1 (ATP6VE1) were up-regulated only in the early stages, and down-regulated in the later stages of AD. The proteins, which were further confirmed by RT-PCR at the mRNA level and with western blotting at the protein level, are expected to be good candidates as drug targets for AD. The study of up- and down-regulation of proteins during the progression of AD helps to explain the mechanisms associated with neuronal degeneration in AD.

Original languageEnglish
Pages (from-to)670-675
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume430
Issue number2
DOIs
Publication statusPublished - 2013 Jan 11

Fingerprint

Proteomics
Transgenic Mice
Brain
Alzheimer Disease
Tissue
Phosphopyruvate Hydratase
Proteins
Mass spectrometry
Carbonic Anhydrase II
Vacuolar Proton-Translocating ATPases
tau Proteins
Neurodegenerative diseases
Neurofibrillary Tangles
Protein S
Electrospray ionization
Amyloid Plaques
Proteome
Tandem Mass Spectrometry
Glutathione Transferase
Liquid chromatography

Keywords

  • Alzheimer's disease
  • ATP6VE1
  • Neurodegenerative disorder
  • SCRN

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease. / Chang, Seong Hun; Jung, In Soo; Han, Gi Yeon; Kim, Nam Hee; Kim, Hyun Jung; Kim, Chan Wha.

In: Biochemical and Biophysical Research Communications, Vol. 430, No. 2, 11.01.2013, p. 670-675.

Research output: Contribution to journalArticle

Chang, Seong Hun ; Jung, In Soo ; Han, Gi Yeon ; Kim, Nam Hee ; Kim, Hyun Jung ; Kim, Chan Wha. / Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease. In: Biochemical and Biophysical Research Communications. 2013 ; Vol. 430, No. 2. pp. 670-675.
@article{df5adf3c8be54d43b4e8f0e3f8fd60a1,
title = "Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) involves regionalized neuronal death, synaptic loss, and an accumulation of intracellular neurofibrillary tangles and extracellular senile plaques. Although there have been numerous studies on tau proteins and AD in various stages of neurodegenerative disease pathology, the relationship between tau and AD is not yet fully understood. A transgenic mouse model expressing neuron-specific enolase (NSE)-controlled human wild-type tau (NSE-htau23), which displays some of the typical Alzheimer-associated pathological features, was used to analyze the brain proteome associated with tau tangle deposition. Two-dimensional electrophoresis was performed to compare the cortex proteins of transgenic mice (6- and 12-month-old) with those of control mice. Differentially expressed spots in different stages of AD were identified with ESI-Q-TOF (electrospray ionization quadruple time-of-flight) mass spectrometry and liquid chromatography/tandem mass spectrometry. Among the identified proteins, glutathione S-transferase P 1 (GSTP1) and carbonic anhydrase II (CAII) were down-regulated with the progression of AD, and secerin-1 (SCRN1) and V-type proton ATPase subunit E 1 (ATP6VE1) were up-regulated only in the early stages, and down-regulated in the later stages of AD. The proteins, which were further confirmed by RT-PCR at the mRNA level and with western blotting at the protein level, are expected to be good candidates as drug targets for AD. The study of up- and down-regulation of proteins during the progression of AD helps to explain the mechanisms associated with neuronal degeneration in AD.",
keywords = "Alzheimer's disease, ATP6VE1, Neurodegenerative disorder, SCRN",
author = "Chang, {Seong Hun} and Jung, {In Soo} and Han, {Gi Yeon} and Kim, {Nam Hee} and Kim, {Hyun Jung} and Kim, {Chan Wha}",
year = "2013",
month = "1",
day = "11",
doi = "10.1016/j.bbrc.2012.11.093",
language = "English",
volume = "430",
pages = "670--675",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease

AU - Chang, Seong Hun

AU - Jung, In Soo

AU - Han, Gi Yeon

AU - Kim, Nam Hee

AU - Kim, Hyun Jung

AU - Kim, Chan Wha

PY - 2013/1/11

Y1 - 2013/1/11

N2 - Alzheimer's disease (AD) involves regionalized neuronal death, synaptic loss, and an accumulation of intracellular neurofibrillary tangles and extracellular senile plaques. Although there have been numerous studies on tau proteins and AD in various stages of neurodegenerative disease pathology, the relationship between tau and AD is not yet fully understood. A transgenic mouse model expressing neuron-specific enolase (NSE)-controlled human wild-type tau (NSE-htau23), which displays some of the typical Alzheimer-associated pathological features, was used to analyze the brain proteome associated with tau tangle deposition. Two-dimensional electrophoresis was performed to compare the cortex proteins of transgenic mice (6- and 12-month-old) with those of control mice. Differentially expressed spots in different stages of AD were identified with ESI-Q-TOF (electrospray ionization quadruple time-of-flight) mass spectrometry and liquid chromatography/tandem mass spectrometry. Among the identified proteins, glutathione S-transferase P 1 (GSTP1) and carbonic anhydrase II (CAII) were down-regulated with the progression of AD, and secerin-1 (SCRN1) and V-type proton ATPase subunit E 1 (ATP6VE1) were up-regulated only in the early stages, and down-regulated in the later stages of AD. The proteins, which were further confirmed by RT-PCR at the mRNA level and with western blotting at the protein level, are expected to be good candidates as drug targets for AD. The study of up- and down-regulation of proteins during the progression of AD helps to explain the mechanisms associated with neuronal degeneration in AD.

AB - Alzheimer's disease (AD) involves regionalized neuronal death, synaptic loss, and an accumulation of intracellular neurofibrillary tangles and extracellular senile plaques. Although there have been numerous studies on tau proteins and AD in various stages of neurodegenerative disease pathology, the relationship between tau and AD is not yet fully understood. A transgenic mouse model expressing neuron-specific enolase (NSE)-controlled human wild-type tau (NSE-htau23), which displays some of the typical Alzheimer-associated pathological features, was used to analyze the brain proteome associated with tau tangle deposition. Two-dimensional electrophoresis was performed to compare the cortex proteins of transgenic mice (6- and 12-month-old) with those of control mice. Differentially expressed spots in different stages of AD were identified with ESI-Q-TOF (electrospray ionization quadruple time-of-flight) mass spectrometry and liquid chromatography/tandem mass spectrometry. Among the identified proteins, glutathione S-transferase P 1 (GSTP1) and carbonic anhydrase II (CAII) were down-regulated with the progression of AD, and secerin-1 (SCRN1) and V-type proton ATPase subunit E 1 (ATP6VE1) were up-regulated only in the early stages, and down-regulated in the later stages of AD. The proteins, which were further confirmed by RT-PCR at the mRNA level and with western blotting at the protein level, are expected to be good candidates as drug targets for AD. The study of up- and down-regulation of proteins during the progression of AD helps to explain the mechanisms associated with neuronal degeneration in AD.

KW - Alzheimer's disease

KW - ATP6VE1

KW - Neurodegenerative disorder

KW - SCRN

UR - http://www.scopus.com/inward/record.url?scp=84872308610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872308610&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2012.11.093

DO - 10.1016/j.bbrc.2012.11.093

M3 - Article

C2 - 23211594

AN - SCOPUS:84872308610

VL - 430

SP - 670

EP - 675

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 2

ER -